- Home
- LANV vs ABEO Comparison
LANV vs ABEO Comparison
Compare LANV & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- ABEO
- Stock Information
- Founded
- LANV 2015
- ABEO N/A
- Country
- LANV China
- ABEO United States
- Employees
- LANV N/A
- ABEO N/A
- Industry
- LANV Blank Checks
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- ABEO Health Care
- Exchange
- LANV Nasdaq
- ABEO Nasdaq
- Market Cap
- LANV 219.4M
- ABEO 243.9M
- IPO Year
- LANV N/A
- ABEO 1980
- Fundamental
- Price
- LANV $2.02
- ABEO $5.09
- Analyst Decision
- LANV
- ABEO Strong Buy
- Analyst Count
- LANV 0
- ABEO 3
- Target Price
- LANV N/A
- ABEO $18.00
- AVG Volume (30 Days)
- LANV 65.3K
- ABEO 251.8K
- Earning Date
- LANV 02-19-2025
- ABEO 11-14-2024
- Dividend Yield
- LANV N/A
- ABEO N/A
- EPS Growth
- LANV N/A
- ABEO N/A
- EPS
- LANV N/A
- ABEO N/A
- Revenue
- LANV $409,961,427.00
- ABEO N/A
- Revenue This Year
- LANV N/A
- ABEO N/A
- Revenue Next Year
- LANV $10.45
- ABEO $15,721.96
- P/E Ratio
- LANV N/A
- ABEO N/A
- Revenue Growth
- LANV N/A
- ABEO 147.52
- 52 Week Low
- LANV $0.91
- ABEO $3.05
- 52 Week High
- LANV $3.78
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- LANV 54.08
- ABEO 33.22
- Support Level
- LANV $1.38
- ABEO $5.05
- Resistance Level
- LANV $2.46
- ABEO $5.66
- Average True Range (ATR)
- LANV 0.28
- ABEO 0.26
- MACD
- LANV 0.01
- ABEO -0.05
- Stochastic Oscillator
- LANV 62.04
- ABEO 8.49
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.